Leave a little sharper than you arrived.

News, calculators, learning and daily puzzles — pick any one and leave a little further along.

Today’s puzzle

Retatrutide outperforms Ozempic on blood sugar and weight loss in head-to-head trial

Eli Lilly's triple agonist retatrutide beat Ozempic in a direct head-to-head phase 3 trial for type 2 diabetes. Both the 9 mg and 12 mg doses of retatrutide cut HbA1c by 2.2 percentage points vs. 1.8 with Ozempic, and delivered more than double the weight loss — up to 20.9% vs. 9.4%. The drug isn't approved yet, but Lilly says it could shift the treatment landscape for diabetes and obesity.

OncLive · 2 min

T-DXd wins EU approval for early HER2+ breast cancer — and it's now cleared in multiple major markets

Healio · 2 min

Osimertinib + savolitinib sets a new standard of care for EGFR-mutant lung cancer

Medscape · 3 min

Long-acting HIV injections prove effective for patients who struggle with daily pills

Everything on Curie.MD

NeurologyPlay & LearnLearn what’s new in your field, a few minutes at a time.Start learning CardiologyCalculatorsEnter the case once. See every relevant score, side by side.Open a calculator All fieldsDaily GamesThree new clinical puzzles every morning.Play today

Get Curie’s Weekly Dose

What changed in clinical practice, policy, and coverage, and what it means for your patients.

Subscribe free Free. Weekly. Unsubscribe anytime.